Short-term Evaluation of Motor and Sensory Function in Post-COVID-19 Patients

Sensory Neuropathy Clinical Trial

Official title: Short-term Evaluation of Motor and Sensory Function in Post-COVID-19 Patients

Status Completed

Clinical Trial Summary

SARS-COV-2 infection reframed medical knowledge in many aspects, yet there is still a lot to be discovered. our aim is to evaluate neurological impact of covid-19; if there is any.

Clinical Trial Description

Coronavirus disease 19 (COVID-19) can cause neuropsychiatric, psychological and psychosocial impairments. Literature regarding the sensory and motor affection of COVID-19 is still limited. Public health emergencies as COVID-19 are likely to cause adverse neuropsychiatric impacts. Cognitive impairments after SARS-COV-2 infection were noticed, COVID-19 patients complain of poor concentration, declined memory, and insomnia, as well as anxiety and depression symptoms. in a study; Neurological manifestations described in 36.4% of 214 patients with confirmed COVID-19. However, the symptoms described [dizziness (not further defined), headache, and impaired consciousness] are commonplace in many severe infections and represent disturbances in neurological function rather than a neurological disease per se. Anosmia and ageusia have received much attention, but are ubiquitous in other common upper respiratory tract infections. While a reported increased risk of cerebrovascular disease. ;

Related Conditions & MeSH terms

• COVID-19
• Motor Neuropathy
• Peripheral Nervous System Diseases
• Sensory Neuropathy

• NCT number: NCT05721040
• Study type: Observational
• Source: Assiut University
• Status: Completed
• Start date: October 1, 2021
• Completion date: September 1, 2022